Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)

Next Previous
X
Search
Trial Profile

Study of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitisinone (Primary)
  • Indications Tyrosinaemia type I
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Jun 2016 New trial record
    • 15 Jun 2016 According to Swedish Orphan Biovitrum media release, the company announced that the Food and Drug Administration (FDA) has approved a higher strength 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top